Triple therapy shows promise for intermediate liver cancer

NCT ID NCT05332496

Completed Disease control Sponsor: Zhongda Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. The goal was to see if this combination improves how long patients live without their cancer getting worse. The study is complete, but full results are still pending.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PD-1/PD-L1 inhibitors (e.g., atezolizumab, pembrolizumab) and VEGF-TKI/bevacizumab (e.g., sorafenib, lenvatinib)
What this could lead to: If successful, this combination could offer a new standard treatment to control intermediate-stage liver cancer and extend survival without needing lifelong medication.
What could go wrong: This is a completed study, but results are not yet published. The combination may cause serious side effects, and not all patients may benefit equally.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Gao-Jun Teng

Nanjing, China
Zheng-Gang Ren

Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.